If you are waiting for a cheaper generic version of Eliquis, here is the short version: it has been approved by the FDA since 2019, but you cannot buy it in a US pharmacy until at least April 1, 2028. That gap is not about safety or science — it is about patents and the legal settlements that protect them. SunnyPharma is an independent health education platform; we do not sell medication, and we have no stake in whether you wait or switch. This page explains the timeline honestly and, more importantly, what you can do about your cost in the roughly two years until the generic arrives.
Generic apixaban (generic Eliquis) is FDA-approved but blocked from US pharmacies until April 1, 2028 by patent settlements. You may see “November 2026” cited — that is when one patent expires, not when a generic reaches your pharmacy. Until 2028, you can lower your Eliquis cost through the copay card, patient assistance, or Medicare programs — you do not have to wait, and you should never stop taking it to save money.
- Generic apixaban has been FDA-approved since 2019 — the delay is legal, not a safety question.
- The earliest US launch is April 1, 2028, set by patent settlements and upheld in court.
- November 2026 is a patent-expiry date, not an availability date — a separate formulation patent blocks generics until 2028.
- Prices usually drop modestly at first, then more sharply as multiple generics enter (2028–2029).
- You can lower your cost right now — copay card, patient assistance, or Medicare programs — without waiting.
- Never stop Eliquis to wait for the generic. Stopping early raises clot and stroke risk (boxed warning).
When Generic Eliquis Will Actually Be Available
The single most reliable date is April 1, 2028. That is the earliest generic manufacturers are legally permitted to launch apixaban in the United States, according to Bristol Myers Squibb and confirmed by federal court rulings — though it remains subject to further appeals and challenges. The FDA approved generic apixaban from multiple manufacturers back in 2019, so the medication itself is ready; what is not ready is the legal clearance to sell it.
When generics do arrive, expect the price to ease gradually. Industry experience is that a single early generic produces only modest savings, with bigger drops once several manufacturers compete — likely developing over 2028 to 2029.
Why You See “November 2026” — and Why It’s Misleading
Many articles mention a 2026 date, and it causes real confusion for patients trying to plan. Here is the distinction that clears it up: a patent expiring is not the same as a generic becoming available.
Eliquis is protected by more than one patent. The original compound patent — covering apixaban itself — has an extended term that runs out around November 2026. But Bristol Myers Squibb and Pfizer also hold a separate formulation patent, and they reached settlement agreements with generic manufacturers that, together with court rulings, push the earliest launch to April 1, 2028. So the 2026 date is a real milestone in the patent paperwork, but it is not the day a cheaper generic shows up at your pharmacy counter. If you are planning your finances, plan around 2028.
Why It’s Taking So Long When the FDA Already Approved It
This is the part that frustrates patients most, and it is worth understanding. FDA approval and the legal right to sell are two separate things:
- The FDA confirmed the generics work. In 2019 it approved generic apixaban from multiple companies, verifying they are bioequivalent to brand Eliquis.
- Patents still block the sale. BMS and Pfizer hold follow-on patents beyond the original compound patent, and they have successfully defended them in litigation, including a Federal Circuit appeals ruling.
- Settlements set the launch date. Rather than risk losing in court, generic makers agreed to settlement terms that delay their launch — the source of the April 1, 2028 date.
The result is a multi-year window in which an FDA-approved, lower-cost version exists but cannot legally be sold in the US. Patient-advocacy analysts have estimated the brand earns billions in additional revenue during exactly this gap.
What to Do About Cost Until 2028
This is the practical heart of it: you do not have to wait until 2028 to pay less. The right move depends on your coverage today.
| Your situation | Best current option | Where to go |
|---|---|---|
| Commercial insurance | Manufacturer copay card (as low as $10/mo) | Eliquis Coupon & Savings Card |
| Uninsured / underinsured | Patient assistance (free if eligible) | Eliquis Patient Assistance |
| Medicare | 2026 negotiated price, Part D cap, Extra Help | Eliquis on Medicare |
| Any — clinical fit | Ask about a lower-cost alternative anticoagulant | Your prescriber |
Do not stop or ration Eliquis while you wait for the generic. Eliquis carries a boxed warning: stopping it early increases the risk of blood clots and stroke. The generic is years away; your clot risk is immediate. If cost is forcing the decision, use the programs above or talk to your prescriber before you skip a single dose.
Generic Apixaban Already Exists Abroad
Generic apixaban is already sold in other countries, including Canada, where multiple manufacturers market it in the same strengths as Eliquis (commonly 2.5 mg and 5 mg) under Health Canada bioequivalence standards. It is chemically the same medicine.
That said, personal importation of prescription drugs into the US is not authorized by the FDA and sits in a legal gray area. A foreign generic is not a way to “skip” the 2028 wait through SunnyPharma — we do not sell, supply, or facilitate medication purchases. We mention it only so the picture is complete. If you are considering it, discuss it with your prescriber and understand the regulatory status first.
Will the Generic Actually Be Cheaper — and By How Much?
Generics almost always cost less than brand drugs, but the size of the drop depends on competition. With a single early generic, savings tend to be modest because there is little price pressure. As more manufacturers enter, prices fall further. Reporting indicates 13 companies have filed for generic apixaban, so once the gate opens in 2028 a competitive market could develop over 2028 to 2029 — which is typically when the larger savings materialize. Exactly how low the price goes will depend on how many generics launch and how quickly.
Frequently Asked Questions
Is there a generic for Eliquis?
Generic versions of apixaban (the active ingredient in Eliquis) were approved by the FDA in 2019, but they are not yet sold in US pharmacies. Patent settlements and court rulings block their commercial launch until at least April 1, 2028. Until then, US pharmacies dispense only brand-name Eliquis. Generic apixaban is already sold in other countries, including Canada.
When will generic Eliquis be available in the US?
The earliest generic apixaban can legally launch in US pharmacies is April 1, 2028, according to Bristol Myers Squibb and confirmed by federal court rulings, subject to further appeals. A broader, more competitive multi-generic market is likely to develop over 2028 to 2029. This is a launch date set by patent settlements, not an FDA approval issue; the FDA approved generic apixaban back in 2019.
Doesn’t the Eliquis patent expire in November 2026?
The main compound patent’s extended term expires around November 2026, which is why you may see that date cited. But patent expiry is not the same as generic availability. A separate formulation patent and court-upheld settlement agreements block generic launch until April 1, 2028. So November 2026 is a patent milestone, not the date a cheaper generic reaches your pharmacy. Plan around April 2028, not 2026.
Why is generic Eliquis taking so long if the FDA already approved it?
FDA approval and the legal right to sell are two different things. The FDA approved generic apixaban from multiple manufacturers in 2019, confirming the generics are safe and bioequivalent. But Bristol Myers Squibb and Pfizer hold additional patents and won litigation that lets them block sales of those approved generics until April 1, 2028. The delay is a patent and settlement matter, not a safety or quality concern.
What can I do to lower my Eliquis cost before the generic arrives?
Your options depend on your coverage. With commercial insurance, the manufacturer copay card can lower your cost to as little as $10 a month. If you are uninsured or underinsured and income-eligible, the Bristol Myers Squibb Patient Assistance Foundation may provide Eliquis free. If you have Medicare, the 2026 negotiated price, the Part D out-of-pocket cap, and Extra Help apply. Discuss any clinically appropriate lower-cost anticoagulant with your prescriber. You do not have to wait until 2028 to reduce what you pay.
Is Canadian generic apixaban the same as Eliquis?
Yes, chemically. Generic apixaban sold in Canada is the same active ingredient at equivalent strengths (commonly 2.5 mg and 5 mg) and meets Health Canada bioequivalence standards. However, personal importation of prescription drugs into the US is not authorized by the FDA and sits in a legal gray area. SunnyPharma does not sell or facilitate medication purchases. Any switch should be discussed with your prescriber.
Will Eliquis get cheaper when the generic launches?
Generic competition usually lowers prices, but often modestly at first when only one or two generics are on the market, then more sharply as additional manufacturers enter. With 13 companies reported to have filed for generic apixaban, a competitive market could develop over 2028 to 2029, which tends to bring larger price drops. The exact savings will depend on how many generics launch and how quickly.
Should I stop taking Eliquis to wait for the generic?
No. Never stop or skip Eliquis to wait for a cheaper version. Eliquis carries a boxed warning that stopping it early raises the risk of blood clots and stroke. If cost is a problem now, use the copay card, patient assistance, Medicare programs, or a prescriber-approved alternative rather than going without. The generic is years away; your clot and stroke risk is immediate.
How we reviewed this article:
Richard Boehme researched and wrote this guide using Bristol Myers Squibb and Pfizer public statements on the Eliquis patent litigation, the U.S. Court of Appeals for the Federal Circuit ruling, FDA generic-approval records, and independent patent analysis from I-MAK. Dr. Elizabeth Swiggum, a cardiologist, reviewed the clinical content — including the boxed-warning caution against stopping anticoagulation for cost — for accuracy.
Sources & References
- Bristol Myers Squibb / Pfizer. Statement on the U.S. Court of Appeals for the Federal Circuit decision upholding the Eliquis patents (earliest generic launch April 1, 2028). news.bms.com; pfizer.com.
- I-MAK. Overpatented, Overpriced: Eliquis patent and exclusivity analysis (‘208 compound patent, ‘945 formulation patent). i-mak.org.
- U.S. Food & Drug Administration. Generic apixaban approvals (2019); Orange Book patent & exclusivity data.
- Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program — Eliquis 2026 negotiated price. CMS.gov.
- U.S. Food & Drug Administration. Personal importation of prescription drugs — policy and limitations. FDA.gov.